{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:05:38Z","timestamp":1794254738551,"version":"4.9.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Carrier screening is a term used to describe genetic testing that is performed on an individual who does not have any overt phenotype for a genetic disorder but may have one variant allele within a gene(s) associated with a diagnosis. Information about carrier screening should be provided to every pregnant woman. Carrier screening and counseling ideally should be performed before pregnancy because this enables couples to learn about their reproductive risk and consider the most complete range of reproductive options. A patient may decline any or all screening. When an individual is found to be a carrier for a genetic condition, his or her relatives are at risk of carrying the same mutation. The patient should be encouraged to inform his or her relatives of the risk and the availability of carrier screening. If an individual is found to be a carrier for a specific condition, the patient\u2019s reproductive partner should be offered testing in order to receive informed genetic counseling about potential reproductive outcomes. If both partners are found to be carriers of a genetic condition, genetic counseling should be offered. What follows is a detailed discussion of some of the more common genetic conditions for which carrier screening is recommended in at least some segments of the population.<\/jats:p>","DOI":"10.1097\/aog.0000000000001952","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T11:47:16Z","timestamp":1487850436000},"page":"e41-e55","source":"Crossref","is-referenced-by-count":398,"title":["Committee Opinion No. 691: Carrier Screening for Genetic Conditions"],"prefix":"10.1097","volume":"129","member":"276","reference":[{"key":"R1-20230711","first-page":"747","article-title":"Committee Opinion No. 478. American College of Obstetricians and Gynecologists","volume":"117","year":"2011","journal-title":"Obstet Gynecol"},{"key":"R2-20230711","first-page":"1538","article-title":"Committee Opinion No. 634. American College of Obste-tricians and Gynecologists","volume":"125","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R3-20230711","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/GIM.0b013e318188d069","article-title":"Carrier screening for spinal muscular atrophy. Professional Practice and Guidelines Committee","volume":"10","author":"Prior","year":"2008","journal-title":"Genet Med"},{"key":"R4-20230711","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/ajmg.a.33474","article-title":"Newborn and carrier screening for spinal muscular atrophy","volume":"152A","author":"Prior","year":"2010","journal-title":"Am J Med Genet A"},{"key":"R5-20230711","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00125817-200201000-00004","article-title":"Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2","volume":"4","author":"Mailman","year":"2002","journal-title":"Genet Med"},{"key":"R6-20230711","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.GIM.0000139506.11694.7C","article-title":"Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel [published errata appear in Genet Med 2005;7:286; Genet Med 2004;6:548]","volume":"6","author":"Watson","year":"2004","journal-title":"Genet Med"},{"key":"R10-20230711","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/01.GIM.0000139506.11694.7C","article-title":"Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel","volume":"6","author":"Watson","year":"2004","journal-title":"Genet Med"},{"key":"R11-20230711","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S.","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"key":"R12-20230711","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4030","article-title":"Screening for sickle cell disease and thalassaemia: a systematic review with supplementary research","volume":"4","author":"Davies","year":"2000","journal-title":"Health Technol Assess"},{"key":"R14-20230711","first-page":"209","article-title":"The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990","volume":"27","author":"Kazazian","year":"1990","journal-title":"Semin Hematol"},{"key":"R16-20230711","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/ajmg.a.31286","article-title":"Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP","volume":"140A","author":"Hatton","year":"2006","journal-title":"Am J Med Genet A"},{"key":"R17-20230711","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/GIM.0b013e31818c2606","article-title":"Clinical significance of tri-nucleotide repeats in Fragile X testing: a clarification of American College of Medical Genetics guidelines","volume":"10","author":"Kronquist","year":"2008","journal-title":"Genet Med"},{"key":"R18-20230711","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/gim.2013.61","article-title":"ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics","volume":"15","author":"Monaghan","year":"2013","journal-title":"Genet Med"},{"key":"R19-20230711","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/1097-0223(200008)20:8<611::AID-PD881>3.0.CO;2-M","article-title":"Screening for fragile X syndrome in women of reproductive age","volume":"20","author":"Pesso","year":"2000","journal-title":"Prenat Diagn"},{"key":"R20-20230711","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1097\/AOG.0b013e318163be0b","article-title":"Prevalence and instability of fragile X alleles: implications for offering fragile X prenatal diagnosis","volume":"111","author":"Cronister","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R21-20230711","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00439-002-0723-5","article-title":"Timing of the absence of FMR1 expression in full mutation chorionic villi","volume":"110","author":"Willemsen","year":"2002","journal-title":"Hum Genet"},{"key":"R22-20230711","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/ajmg.10450","article-title":"Familial dysautonomia: detection of the IKBKAP IVS20(+6T--> C) and R696P mutations and frequencies among Ashkenazi Jews","volume":"110","author":"Dong","year":"2002","journal-title":"Am J Med Genet"},{"key":"R24-20230711","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/mgg3.37","article-title":"Next-generation DNA sequencing of HEXA: a step in the right direction for carrier screening","volume":"1","author":"Hoffman","year":"2013","journal-title":"Mol Genet Genomic Med"},{"key":"R25-20230711","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/jmg.33.10.829","article-title":"Heterozygosity for Tay\u2013Sachs disease in non-Jewish Americans with ancestry from Ireland or Great Britain","volume":"33","author":"van Bael","year":"1996","journal-title":"J Med Genet"},{"key":"R26-20230711","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/ajmg.a.33085","article-title":"Population-based Tay\u2013Sachs screening among Ashkenazi Jewish young adults in the 21st century: Hexosaminidase A enzyme assay is essential for accurate testing","volume":"149A","author":"Schneider","year":"2009","journal-title":"Am J Med Genet A"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006250-201703000-00048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T18:08:23Z","timestamp":1689098903000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006250-201703000-00048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000001952","relation":{},"ISSN":["0029-7844"],"issn-type":[{"value":"0029-7844","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}